141 related articles for article (PubMed ID: 18783957)
1. Concentrations of piperacillin-tazobactam in human jaw and hip bone.
Al-Nawas B; Kinzig-Schippers M; Soergel F; Shah PM
J Craniomaxillofac Surg; 2008 Dec; 36(8):468-72. PubMed ID: 18783957
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
[TBL] [Abstract][Full Text] [Related]
3. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Chandorkar G; Huntington JA; Gotfried MH; Rodvold KA; Umeh O
J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-tazobactam penetration into human pancreatic juice.
Bertazzoni Minelli E; Benini A; Franco L; Bassi C; Pederzoli P
Antimicrob Agents Chemother; 2008 Nov; 52(11):4149-52. PubMed ID: 18809943
[TBL] [Abstract][Full Text] [Related]
5. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
Incavo SJ; Ronchetti PJ; Choi JH; Wu H; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1994 Apr; 38(4):905-7. PubMed ID: 8031071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characteristics of piperacillin/tazobactam.
Sörgel F; Kinzig M
Intensive Care Med; 1994 Jul; 20 Suppl 3():S14-20. PubMed ID: 7962984
[TBL] [Abstract][Full Text] [Related]
7. Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.
Boselli E; Breilh D; Debon R; Duflo F; Bel JC; Saux MC; Chassard D; Allaouchiche B
J Chemother; 2002 Feb; 14(1):54-8. PubMed ID: 11892900
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
Cheatham SC; Fleming MR; Healy DP; Chung CE; Shea KM; Humphrey ML; Kays MB
Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
[TBL] [Abstract][Full Text] [Related]
11. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
13. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
Felton TW; McCalman K; Malagon I; Isalska B; Whalley S; Goodwin J; Bentley AM; Hope WW
Clin Pharmacol Ther; 2014 Oct; 96(4):438-48. PubMed ID: 24926779
[TBL] [Abstract][Full Text] [Related]
16. An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers.
Xia CH; Xiong YQ; Wang GJ
Biomed Chromatogr; 2007 Jul; 21(7):680-6. PubMed ID: 17385803
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
20. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
